Treating Cancer and Metabolic Dysfunction
As a young company in the crowded pharma and oncology space, SynDevRx needed to find a way to quickly define their value offering. Metropolis helped them achieve that with a fresh design, custom diagrams, and clear copywriting from The Hired Pens. The new website design is fully content-managed and responsive for any screen size.
Metabo-oncology — which focuses on the link between cancer and metabolic dysfunction — is poised to spark a paradigm shift in cancer treatment. SynDevRx is the leader in this emerging field. Their lead compound, SDX-7320 is a methionine aminopeptidase type II (MetAP2) inhibitor that proposes to both treat the tumor directly and correct the underlying metabolic dysfunction — sort of a one-two punch to cancer.Back to Archive